Table 3. Top three metabolites associated with each AD-related trait.
Metabolite | AD-related trait | p-value | FDR | Effect direction |
---|---|---|---|---|
carboxyethyl-GABA | β-amyloid | 1.47E-08 | 9.79E-06 | Positive |
1-stearoyl-2-oleoyl-GPE (18:0/18:1) | β-amyloid | 2.01E-06 | 3.46E-04 | Negative |
glycerophosphoethanolamine | β-amyloid | 2.08E-06 | 3.46E-04 | Positive |
glycerophosphoethanolamine | Tau tangles | 1.28E-07 | 8.54E-05 | Positive |
glycerophosphorylcholine (GPC) | Tau tangles | 4.46E-07 | 1.49E-04 | Positive |
1-stearoyl-2-arachidonoyl-GPE (18:0/20:4) | Tau tangles | 2.84E-06 | 1.90E-04 | Negative |
N-acetylglutamate | Global NP | 5.39E-11 | 3.59E-08 | Negative |
N-acetylputrescine | Global NP | 3.61E-10 | 1.20E-07 | Negative |
glycerophosphoethanolamine | Global NP | 1.34E-09 | 2.97E-07 | Positive |
carboxyethyl-GABA | NIA Reagan | 1.39E-07 | 9.25E-05 | Positive |
glycerophosphoethanolamine | NIA Reagan | 5.39E-06 | 1.80E-03 | Positive |
X - 25109 | NIA Reagan | 1.15E-05 | 2.55E-03 | Negative |
1-stearoyl-2-oleoyl-GPE (18:0/18:1) | NP Diagnosis | 2.86E-06 | 6.45 E-04 | Negative |
allo-threonine | NP Diagnosis | 2.90E-06 | 6.45 E-04 | Positive |
glycerophosphoethanolamine | NP Diagnosis | 2.10E-06 | 6.45 E-04 | Positive |
glycerophosphoethanolamine | Clinical Diagnosis | 2.75E-11 | 1.83E-08 | Positive |
glycerophosphorylcholine (GPC) | Clinical Diagnosis | 3.72E-10 | 8.26E-08 | Positive |
N-acetyl-aspartyl-glutamate (NAAG) | Clinical Diagnosis | 3.64E-10 | 8.26E-08 | Positive |
glycerophosphoethanolamine | Cognition | 3.09E-12 | 2.06E-09 | Positive |
glycerophosphorylcholine (GPC) | Cognition | 2.34E-10 | 7.81E-08 | Positive |
myo-inositol | Cognition | 1.13E-08 | 1.89E-06 | Positive |
glycerophosphoethanolamine | Cognitive Decline | 1.06E-15 | 7.05E-13 | Positive |
glycerophosphorylcholine (GPC) | Cognitive Decline | 4.75E-14 | 1.58E-11 | Positive |
X - 24035 | Cognitive Decline | 5.98E-13 | 1.33E-10 | Positive |